Ballentine Partners LLC Buys 984 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ballentine Partners LLC lifted its stake in Edwards Lifesciences Co. (NYSE:EW) by 23.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,236 shares of the medical research company’s stock after purchasing an additional 984 shares during the period. Ballentine Partners LLC’s holdings in Edwards Lifesciences were worth $500,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Edwards Lifesciences by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock worth $3,992,709,000 after acquiring an additional 729,984 shares in the last quarter. Brown Advisory Inc. lifted its holdings in Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after acquiring an additional 3,048,274 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock worth $1,283,098,000 after acquiring an additional 393,109 shares in the last quarter. Norges Bank bought a new position in Edwards Lifesciences during the fourth quarter worth about $648,540,000. Finally, Sands Capital Management LLC lifted its holdings in Edwards Lifesciences by 34.6% during the fourth quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock worth $465,407,000 after acquiring an additional 1,567,526 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on EW. Citigroup upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $98.00 to $105.00 in a report on Wednesday, May 22nd. Piper Sandler boosted their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday, April 26th. Evercore ISI reduced their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a report on Friday, April 26th. Barclays boosted their price objective on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Finally, Mizuho boosted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.06.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,809,931.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Bernard J. Zovighian purchased 580 shares of the stock in a transaction dated Monday, May 6th. The stock was bought at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at $1,809,931.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 127,104 shares of company stock worth $11,267,464. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.8 %

NYSE EW opened at $90.15 on Tuesday. The business has a fifty day moving average price of $87.48 and a two-hundred day moving average price of $84.80. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The stock has a market capitalization of $54.32 billion, a PE ratio of 38.86, a PEG ratio of 3.25 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Equities analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.